A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19

PURPOSE: RECOVERY, ACTT-1, and ACTT-2 trials have demonstrated that utilization of dexamethasone, remdesivir, or a combination of remdesivir with baricitinib leads to mortality benefit and faster time to recovery, respectively. However, no studies have investigated the benefit of triple therapy of d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngo, Dallis Q., Hamid, Kewan, Rana, Haris, Cardinale, Maria, Frenia, Douglas, Ghani, Nabil, Redel, Henry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279094/
https://www.ncbi.nlm.nih.gov/pubmed/35845297
http://dx.doi.org/10.1155/2022/9209618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279094/
https://www.ncbi.nlm.nih.gov/pubmed/35845297
http://dx.doi.org/10.1155/2022/9209618

Ejemplares similares